Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
Anne Roulston, Michal Zimmermann, Robert Papp, et al.
Molecular Cancer Therapeutics (2021) Vol. 21, Iss. 2, pp. 245-256
Open Access | Times Cited: 65

Showing 1-25 of 65 citing articles:

DNA repair defects in cancer and therapeutic opportunities
Jessica L. Hopkins, Li Lan, Lee Zou
Genes & Development (2022) Vol. 36, Iss. 5-6, pp. 278-293
Open Access | Times Cited: 121
DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities
Yasser Abuetabh, Hong Wu, Chengsen Chai, et al.
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 10, pp. 1658-1669
Open Access | Times Cited: 104
The hallmarks of cancer immune evasion
Claudia Galassi, Timothy A. Chan, Ilio Vitale, et al.
Cancer Cell (2024) Vol. 42, Iss. 11, pp. 1825-1863
Closed Access | Times Cited: 70
A new wave of innovations within the DNA damage response
Qi Li, Wenyuan Qian, Yang Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 56
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
Timothy A. Yap, Elisa Fontana, Elizabeth K. Lee, et al.
Nature Medicine (2023) Vol. 29, Iss. 6, pp. 1400-1411
Open Access | Times Cited: 50
Targeting ATR in patients with cancer
Natalie Ngoi, Patrick G. Pilié, Daniel J. McGrail, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 278-293
Closed Access | Times Cited: 24
Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets
Alvina I. Khamidullina, Yaroslav E. Abramenko, Alexandra V. Bruter, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1263-1263
Open Access | Times Cited: 19
Resistance to DNA repair inhibitors in cancer
Joseph S. Baxter, Diana Zatreanu, Stephen J. Pettitt, et al.
Molecular Oncology (2022) Vol. 16, Iss. 21, pp. 3811-3827
Open Access | Times Cited: 53
Targeting ATM and ATR for cancer therapeutics: Inhibitors in clinic
Bhanu Priya, Srimadhavi Ravi, Sivapriya Kirubakaran
Drug Discovery Today (2023) Vol. 28, Iss. 8, pp. 103662-103662
Closed Access | Times Cited: 33
Emerging strategies for cancer therapy by ATR inhibitors
Kimiyoshi Yano, Bunsyo Shiotani
Cancer Science (2023) Vol. 114, Iss. 7, pp. 2709-2721
Open Access | Times Cited: 29
DNA Adducts in Cancer Chemotherapy
Yupeng Li
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5113-5143
Closed Access | Times Cited: 11
Guiding ATR and PARP inhibitor combinations with chemogenomic screens
Michal Zimmermann, Cynthia Bernier, Beatrice Kaiser, et al.
Cell Reports (2022) Vol. 40, Iss. 2, pp. 111081-111081
Open Access | Times Cited: 37
The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy
Frank P. Vendetti, Pinakin Pandya, David A. Clump, et al.
JCI Insight (2023) Vol. 8, Iss. 4
Open Access | Times Cited: 20
Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500)
W. Cameron Black, Abbas Abdoli, Xiuli An, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2349-2368
Closed Access | Times Cited: 8
Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)
Xueqin Huang, Li You, Eugenie Nepovimová, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 15
ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition
Marcus Borenäs, Ganesh Umapathy, Dan E. Lind, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 121, Iss. 1
Open Access | Times Cited: 13
The novel ATR inhibitor M1774 induces replication protein overexpression and broad synergy with DNA-targeted anticancer drugs
Ukhyun Jo, Yasuhiro Arakawa, Astrid Zimmermann, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 7, pp. 911-923
Closed Access | Times Cited: 4
Pyrazolopyridine-based kinase inhibitors for anti-cancer targeted therapy
Pallabi Halder, Anubhav Rai, Vishal Talukdar, et al.
RSC Medicinal Chemistry (2024) Vol. 15, Iss. 5, pp. 1452-1470
Closed Access | Times Cited: 4
Targeting the DNA damage response in cancer
Guffanti Federica, Chiappa Michela, Giovanna Damia
MedComm (2024) Vol. 5, Iss. 11
Open Access | Times Cited: 4
Synthetic lethal strategies for the development of cancer therapeutics
Natalie Ngoi, David Gallo, C. Sevillano, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 4
Reversing Regulatory Safeguards: Targeting the ATR Pathway to Overcome PARP Inhibitor Resistance
Xixi Lin, Yongchang Qiu, Aashish Soni, et al.
Deleted Journal (2025) Vol. 33, Iss. 1, pp. 200934-200934
Open Access
Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)
Anuradha Krishnamurthy, Hong Wang, John C. Rhee, et al.
Cancer Chemotherapy and Pharmacology (2025) Vol. 95, Iss. 1
Closed Access
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR
Haineng Xu, Erin George, David Gallo, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Medicinal chemistry breakthroughs on ATM, ATR, and DNA-PK inhibitors as prospective cancer therapeutics
Ram Lal Sharma, Anshul Mishra, Monika Bhardwaj, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2025) Vol. 40, Iss. 1
Open Access
Conjugated Nanoparticles for Solid Tumor Theranostics: Unraveling the Interplay of Known and Unknown Factors
Vivek P. Chavda, Pankti C. Balar, Lakshmi Vineela Nalla, et al.
ACS Omega (2023) Vol. 8, Iss. 41, pp. 37654-37684
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top